Imricor Medical Systems, Inc.ASX: IMR

2026 Q2 Form 10-Q

· Issued by Imricor Medical Systems, Inc. via ASX

Filed with ASX · · 46 pages · English

Summary by 6ix AI

The report includes unaudited condensed consolidated financial statements, which reflect the company's revenues, expenses, and net loss for the quarter. Overall, the filing aims to inform investors about the company's financial health and operational results during the specified period.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 or ? TRANSITION REPORT PURSUANT TO...

Imricor Medical Systems, Inc. on 6ix

Earlier from Imricor Medical Systems

Later from Imricor Medical Systems

All Imricor Medical Systems news releases